{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T10:26:20Z","timestamp":1758709580050,"version":"3.37.3"},"reference-count":16,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T00:00:00Z","timestamp":1591920000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Virology"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1002\/jmv.25974","type":"journal-article","created":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T12:52:10Z","timestamp":1588683130000},"page":"2302-2303","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["What could be the better choice between ACE inhibitors and AT1R antagonists in coronavirus disease 2019 (COVID\u201019) patients?"],"prefix":"10.1002","volume":"92","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5936-1789","authenticated-orcid":false,"given":"Guglielmina","family":"Froldi","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical and Pharmacological Sciences (DSF) University of Padova  Padova Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,6,12]]},"reference":[{"key":"e_1_2_2_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-004-4243-4"},{"key":"e_1_2_2_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2004.03.001"},{"key":"e_1_2_2_4_1","doi-asserted-by":"publisher","DOI":"10.1113\/expphysiol.2007.040048"},{"key":"e_1_2_2_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1267"},{"key":"e_1_2_2_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature02145"},{"key":"e_1_2_2_7_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb2762"},{"key":"e_1_2_2_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2008.03.004"},{"key":"e_1_2_2_9_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01248-09"},{"key":"e_1_2_2_10_1","first-page":"1","article-title":"Angiotensin\u2010converting enzyme 2 inhibits lung injury induced by respiratory syncytial virus","volume":"6","author":"Gu H","year":"2016","journal-title":"Sci Rep"},{"issue":"3","key":"e_1_2_2_11_1","first-page":"219","article-title":"Inhibitors of RAS might be a good choice for the therapy of COVID\u201019 pneumonia","volume":"43","author":"Sun ML","year":"2020","journal-title":"Zhonghua jie he he hu xi za zhi"},{"key":"e_1_2_2_12_1","first-page":"2019","article-title":"Compensation of ACE2 function for possible clinical management of 2019\u2010nCoV\u2010induced acute lung","volume":"12250","author":"Wu Y","year":"2020","journal-title":"Injury Virol Sin"},{"key":"e_1_2_2_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature03712"},{"key":"e_1_2_2_14_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.104.510461"},{"key":"e_1_2_2_15_1","first-page":"e201624","article-title":"Association of renin\u2010angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID\u201019) infection in Wuhan, China","author":"Li J","year":"2020","journal-title":"JAMA Cardiol"},{"key":"e_1_2_2_16_1","unstructured":"European Medicines Agency.EMA advises continued use of medicines for hypertension heart or kidney disease during COVID\u201019 pandemic.2020 March. pp.1\u20102.https:\/\/www.ema.europa.eu\/en\/news\/ema-advises-continued-use-medicines-hypertension-heart-kidney-disease-during-covid-19-pandemic"},{"key":"e_1_2_2_17_1","unstructured":"Heart Failure Society of America American College of Cardiology American Heart Association.HFSA\/ACC\/AHA statement addresses concerns Re: using RAAS antagonists in COVID\u201019.2020 March.https:\/\/www.acc.org\/latest-in-cardiology\/articles\/2020\/03\/17\/08\/59\/hfsa-acc-aha-statement-addresses-concerns-re-using-raas-antagonists-in-COVID-19"}],"container-title":["Journal of Medical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjmv.25974","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmv.25974","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jmv.25974","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmv.25974","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T15:05:45Z","timestamp":1693839945000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jmv.25974"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,12]]},"references-count":16,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["10.1002\/jmv.25974"],"URL":"https:\/\/doi.org\/10.1002\/jmv.25974","archive":["Portico"],"relation":{},"ISSN":["0146-6615","1096-9071"],"issn-type":[{"type":"print","value":"0146-6615"},{"type":"electronic","value":"1096-9071"}],"subject":[],"published":{"date-parts":[[2020,6,12]]},"assertion":[{"value":"2020-04-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}